242 related articles for article (PubMed ID: 26009281)
1. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression.
Miyazaki K; Yamaguchi M; Imai H; Kobayashi K; Tamaru S; Kobayashi T; Shiku H; Katayama N
Int J Hematol; 2015 Aug; 102(2):188-94. PubMed ID: 26009281
[TBL] [Abstract][Full Text] [Related]
2. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas.
Kobayashi T; Yamaguchi M; Kim S; Morikawa J; Ogawa S; Ueno S; Suh E; Dougherty E; Shmulevich I; Shiku H; Zhang W
Cancer Res; 2003 Jan; 63(1):60-6. PubMed ID: 12517778
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
4. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature.
Suguro M; Tagawa H; Kagami Y; Okamoto M; Ohshima K; Shiku H; Morishima Y; Nakamura S; Seto M
Cancer Sci; 2006 Sep; 97(9):868-74. PubMed ID: 16856881
[TBL] [Abstract][Full Text] [Related]
5. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
Xu-Monette ZY; Tu M; Jabbar KJ; Cao X; Tzankov A; Visco C; Nagarajan L; Cai Q; Montes-Moreno S; An Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Miranda RN; Medeiros LJ; Young KH
Oncotarget; 2015 Mar; 6(8):5615-33. PubMed ID: 25760242
[TBL] [Abstract][Full Text] [Related]
6. [CD5-positive DLBCL: molecular basis and treatment strategies].
Miyazaki K
Rinsho Ketsueki; 2015 Aug; 56(8):1038-44. PubMed ID: 26345564
[TBL] [Abstract][Full Text] [Related]
7. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma.
Tagawa H; Suguro M; Tsuzuki S; Matsuo K; Karnan S; Ohshima K; Okamoto M; Morishima Y; Nakamura S; Seto M
Blood; 2005 Sep; 106(5):1770-7. PubMed ID: 15886317
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
Thakral B; Medeiros LJ; Desai P; Lin P; Yin CC; Tang G; Khoury JD; Hu S; Xu J; Loghavi S; Hu B; Oki Y; Li S
Eur J Haematol; 2017 Apr; 98(4):415-421. PubMed ID: 28039906
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs.
Ueno S; Yamaguchi M; Kimura M; Odagiri H; Shiraki K; Uemoto S; Nakamura N; Zhang W; Shiku H; Kobayashi T
Int J Oncol; 2005 Nov; 27(5):1241-6. PubMed ID: 16211218
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
[TBL] [Abstract][Full Text] [Related]
11. Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas.
Mircean C; Tabus I; Kobayashi T; Yamaguchi M; Shiku H; Shmulevich I; Zhang W
Int J Oncol; 2004 Mar; 24(3):497-504. PubMed ID: 14767533
[TBL] [Abstract][Full Text] [Related]
12. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.
Chuang WY; Chang H; Shih LY; Wang PN; Chang YS; Lin TL; Hung YS; Yeh CJ; Ueng SH; Tang TC; Kuo MC; Dunn P; Wu JH; Kao HW; Ou CW; Wan YL; Hsueh C
Virchows Arch; 2015 Nov; 467(5):571-82. PubMed ID: 26369546
[TBL] [Abstract][Full Text] [Related]
13. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
[TBL] [Abstract][Full Text] [Related]
14. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
Xia Y; Xu-Monette ZY; Tzankov A; Li X; Manyam GC; Murty V; Bhagat G; Zhang S; Pasqualucci L; Visco C; Dybkaer K; Chiu A; Orazi A; Zu Y; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Westin J; Fowler N; Miranda RN; Ok CY; Li Y; Li J; Medeiros LJ; Young KH
Leukemia; 2017 Mar; 31(3):625-636. PubMed ID: 27568520
[TBL] [Abstract][Full Text] [Related]
15. CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition.
Cooper A; Tumuluru S; Kissick K; Venkataraman G; Song JY; Lytle A; Duns G; Yu J; Kotlov N; Bagaev A; Hodkinson B; Srinivasan S; Smith SM; Scott DW; Steidl C; Godfrey JK; Kline J
J Clin Oncol; 2024 Feb; 42(4):467-480. PubMed ID: 38079587
[TBL] [Abstract][Full Text] [Related]
16. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization.
Karnan S; Tagawa H; Suzuki R; Suguro M; Yamaguchi M; Okamoto M; Morishima Y; Nakamura S; Seto M
Genes Chromosomes Cancer; 2004 Jan; 39(1):77-81. PubMed ID: 14603444
[TBL] [Abstract][Full Text] [Related]
17. Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B-cell lymphoma cells and their association with clinical features.
Kobayashi K; Yamaguchi M; Miyazaki K; Imai H; Yokoe K; Ono R; Nosaka T; Katayama N
Cancer Med; 2016 Aug; 5(8):1802-9. PubMed ID: 27184832
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns.
Hallas C; Preukschas M; Tiemann M
Leuk Res; 2019 Jan; 76():107-111. PubMed ID: 30360939
[TBL] [Abstract][Full Text] [Related]
19. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
Yamaguchi M; Nakamura N; Suzuki R; Kagami Y; Okamoto M; Ichinohasama R; Yoshino T; Suzumiya J; Murase T; Miura I; Ohshima K; Nishikori M; Tamaru J; Taniwaki M; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
[TBL] [Abstract][Full Text] [Related]
20. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
